Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis

Interactive Cardiovascular and Thoracic Surgery

Volumn 15, Issue 6, 2012, Pages 954-960

  Toyooka, Shinichi ^a   Kiura, Katsuyuki ^a   Shien, Kazuhiko ^a   Katsui, Kuniaki ^a   Hotta, Katsuyuki ^a   Kanazawa, Susumu ^a   Date, Hiroshi ^b   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Chemotherapy; Induction therapy; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BILOBECTOMY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SLEEVE LOBECTOMY; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; PROPORTIONAL HAZARDS MODELS; RADIATION DOSAGE; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870172668     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs412     Document Type: Article

References (19)

1. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:202S-20S. (Pubitemid 47502808)
2. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
3. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-34. (Pubitemid 28135609)
4. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9. (Pubitemid 29415225)
5. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N et al. Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003;89:795-802. (Pubitemid 37175797)
6. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010;28:3299-306.
7. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-smallcell lung cancer. J Natl Cancer Inst 2007;99:442-50. (Pubitemid 47073567)
8. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
9. Higgins K, Chino JP, Marks LB, Ready N, D'Amico TA, Clough RW et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1462-7.
10. Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A et al. Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N (2) non-small cell lung cancer. Br J Cancer 2002;86:530-3. (Pubitemid 34185087)
11. Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 2004;90:979-84. (Pubitemid 38495815)
12. Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small cell lung cancer with mediastinal lymph node metastasis. Interact CardioVasc Thorac Surg 2012;14:565-9.
13. Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M et al. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol 2012;19: 2685-92.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
15. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: 706-14. (Pubitemid 47357522)
16. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92. (Pubitemid 38101633)
17. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31. (Pubitemid 32015269)
18. Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol 2006;94:599-606. (Pubitemid 44851921)
19. Toyooka S, Soh J, Shien K, Sugimoto S, yamane M, Oto T et al. Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. Eur J Cardiothorac Surg 2012;doi:10.1093/ ejcts/ezs323.